C$7.9 0.3 4.0%
Last Trade - 16/04/21
| Market Cap | £59.1m |
| Enterprise Value | £45.3m |
| Revenue | £12.9m |
| Position in Universe | 860th / 2713 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.4 | 17.9 | 20.8 | 21.5 | 21.4 | 22.3 | 26.5 | 29.8 | +7.7% | ||
| +18.8 | +13.9 | +21.1 | +10.1 | -9.1 | -19.4 | +31.1 | +14.5 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women's Health Unit, which commercializes pharmaceutical products focused on improving family and women's health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. Cathejell is indicated for surface anesthesia and lubrication for various procedures. RepaGyn helps relieve dryness and promotes healing of the vaginal mucosa. It also manufactures and markets Protect-It, a non-toxic product.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | May 19, 1999 |
| Public Since | May 22, 1981 |
| No. of Shareholders: | n/a |
| No. of Employees: | n/a |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | TSX Venture Exchange |
| Shares in Issue | 12,937,366 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 170 Attwell Dr Suite 520, ETOBICOKE, M9W 5Z5, Canada |
| Web | http://www.biosyent.com |
| Phone | +1 905 2060013 |
| Contact | () |
| Auditors | MNP LLP |
As of 16/04/21, shares in Biosyent Inc are trading at C$7.9, giving the company a market capitalisation of £59.1m. This share price information is delayed by 15 minutes.
Shares in Biosyent Inc are currently trading at C$7.9 and the price has moved by 90.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biosyent Inc price has moved by 41.47% over the past year.
Of the analysts with advisory recommendations for Biosyent Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Biosyent Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Biosyent Inc is scheduled to issue upcoming financial results on the following dates:
Biosyent Inc does not currently pay a dividend.
Biosyent Inc does not currently pay a dividend.
Biosyent Inc does not currently pay a dividend.
To buy shares in Biosyent Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Biosyent Inc are currently trading at C$7.9, giving the company a market capitalisation of £59.1m.
Here are the trading details for Biosyent Inc:
Based on an overall assessment of its quality, value and momentum, Biosyent Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Biosyent Inc are currently priced at C$7.9. At that level they are trading at 5.06% premium to the analyst consensus target price of 0.00.
Analysts covering Biosyent Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.38 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biosyent Inc. Over the past six months, the relative strength of its shares against the market has been -4.26%. At the current price of C$7.9, shares in Biosyent Inc are trading at 12.96% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biosyent Inc PE ratio based on its reported earnings over the past 12 months is 27.26. The shares are currently trading at C$7.9.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biosyent Inc's management team is headed by:
Here are the top five shareholders of Biosyent Inc based on the size of their shareholding:
